{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:49:10Z","timestamp":1791150550804,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":3160,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Luitpold"},{"name":"Pharmaceuticals, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1093\/annonc\/mdq438","type":"journal-article","created":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T02:25:02Z","timestamp":1285035902000},"page":"787-793","source":"Crossref","is-referenced-by-count":107,"title":["Phase 3 study of docosahexaenoic acid\u2013paclitaxel versus dacarbazine in patients with metastatic malignant melanoma"],"prefix":"10.1016","volume":"22","author":[{"given":"A.Y.","family":"Bedikian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.C.","family":"DeConti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Conry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Agarwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ernstoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq438_bb0010","first-page":"1149","article-title":"Systemic treatments for advanced cutaneous melanoma","volume":"9","author":"Anderson","year":"1995","journal-title":"Oncology (Williston Park)"},{"key":"10.1093\/annonc\/mdq438_bb0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdq438_bb0020","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2004.04.165","article-title":"Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study","volume":"22","author":"Avril","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq438_bb0025","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","article-title":"Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group","volume":"24","author":"Bedikian","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq438_bb0030","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq438_bb0035","first-page":"168","article-title":"Efficacy of interleukin-2 in the treatment of metastatic melanoma","volume":"1","author":"Allen","year":"1998","journal-title":"Cancer Ther"},{"key":"10.1093\/annonc\/mdq438_bb0040","article-title":"Cisplatin (C), vinblastine (V), DTIC (D) (CVD) versus DTIC alone in metastatic melanoma: preliminary results phase III cancer community oncology program (CCOP)","volume":"12","author":"Buzaid","year":"1993","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdq438_bb0045","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multi-center randomized trial of the Dartmouth regimen versus DTIC in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq438_bb0050","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/1097-0142(19900601)65:11<2478::AID-CNCR2820651114>3.0.CO;2-S","article-title":"A phase II trial of taxol in metastatic melanoma","volume":"65","author":"Legha","year":"1990","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq438_bb0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00194546","article-title":"A phase II study of taxol in patients with malignant melanoma","volume":"9","author":"Einzig","year":"1991","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdq438_bb0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1006004809169","article-title":"Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy","volume":"16","author":"Einzig","year":"1998","journal-title":"Invest New Drugs"},{"issue":"Suppl 16","key":"10.1093\/annonc\/mdq438_bb0065","first-page":"725","article-title":"A 2-stage controlled phase 1\/2 study of STA-4783 in combination with paclitaxel in patients with advanced metastatic melanoma abstract","volume":"23","author":"Powderly","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq438_bb0070","first-page":"3589","article-title":"Phase I study of DHA-paclitaxel, a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile","volume":"9","author":"Wolff","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq438_bb0075","unstructured":"Data On File. Shirley, NY: Luitpold Pharmaceuticals, Inc"},{"key":"10.1093\/annonc\/mdq438_bb0080","first-page":"3229","article-title":"Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel","volume":"7","author":"Bradley","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1093\/annonc\/mdq438_bb0085","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/01243894-200611000-00011","article-title":"DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial","volume":"1","author":"Payne","year":"2006","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdq438_bb0090","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00280-007-0486-8","article-title":"A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma","volume":"61","author":"Jones","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdq438_bb0095","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":"Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq438_bb0100","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.0006-341X.2003.00090.x","article-title":"Flexible implementations of group sequential stopping rules using constrained boundaries","volume":"59","author":"Burington","year":"2003","journal-title":"Biometrics"},{"issue":"5","key":"10.1093\/annonc\/mdq438_bb0105","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/00008390-200310000-00012","article-title":"Randomized phase \/I study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG)","volume":"13","author":"Zimpfer-Rechner","year":"2003","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdq438_bb0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00008390-200402000-00010","article-title":"Phase I evaluation of paclitaxel by short intravenous infusion in metastatic melanoma","volume":"14","author":"Bedikian","year":"2004","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdq438_bb0115","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00008390-200510000-00015","article-title":"Phase I trial of weekly paclitaxel in patients with advanced melanoma","volume":"15","author":"Walker","year":"2005","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdq438_bb0120","first-page":"571a","article-title":"Phase II trial of weekly paclitaxel as 2nd line treatment for metastatic melanoma (MMM)","volume":"19","author":"Zonder","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdq438_bb0125","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq438_bb0130","unstructured":"Patel PM, Suciu L, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV malignant melanoma: final results of the randomized phase III study (EORTC 18032). 33rd European Society of Medical Oncology (ESMO) Congress 2008 (AbstLBA8). 1 December 2008."},{"key":"10.1093\/annonc\/mdq438_bb0135","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/CMR.0b013e32832a1e2f","article-title":"Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients","volume":"19","author":"Homsi","year":"2009","journal-title":"Melanoma Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419385503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419385503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/4\/787\/568212\/mdq438.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:24:02Z","timestamp":1624699442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419385503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0923753419385503"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq438","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}